Single-nucleotide polymorphisms (SNPs) related to hereditary thrombophilia were investigated as risk factors for thromboembolism in cancer patients. Their effect in metastatic colorectal cancer (mCRC) has never been explored so far. Our aim was to analyse the effect of coagulation factor V (FVL G1691A), prothrombin (PT G20210A), methylenetetrahydrofolate reductase (MTHFR C677T and A1298C) and plasminogen activator inhibitor type 1 (PAI-1 5G/4G) allelic variants in this setting. Fifty-two patients treated with first-line chemotherapy plus bevacizumab who developed a thromboembolic event in their lifetime were initially genotyped. A contemporary cohort of 127 patients who did not experience any thromboembolic event was also analysed. DNA was extracted from peripheral blood and genotypes were determined by real-time PCR, using LightSNiP (TIB MOLBIOL) on LightCcler 480 (Roche). The association between thromboembolism and SNPs was investigated by univariable and multivariable analyses. All SNPs were in Hardy–Weinberg equilibrium (χ2 test P>0.20). FVL G1691A and PT G20210A were present only in heterozygosis in 4 (2.2%) and 7 (3.9%) patients, respectively; MTHFR C677T in homozygosis in 29 (16.2%), MTHFR A1298C in homozygosis in 13 (7.3%); PAI-1 5G/4G in 98 (54.7%) and 4G/4G in 41 (23%) patients. At univariable analysis, treatment duration was significantly associated with thromboembolism (P<0.001), whereas gender, age, obesity, platelets count and chemotherapy backbone were not. Similarly, FVL G1691A and PT G20210A as well as MTHFR C677T and PAI-1 4G allele were significantly associated, whereas MTHFR A1298C was not. At multivariable model including PT G20210A, MTHFR C677T and PAI-1 4G (age, obesity, treatment duration and chemotherapy backbone were included as adjustment factors), the three SNPs were significantlty associated with higher risk of thromboembolism (P=0.025, <0.0001 and P=0.033, respectively). Further validation studies are warranted in order to design a prospective trial of thromboprophylaxis in mCRC patients with high-risk genotypes.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $19.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE . Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60–68.
Martinelli I, De Stefano V, Mannucci PM . Inherited risk factors for venous thromboembolism. Nat Rev Cardiol 2014; 11: 140–156.
Bertina RM, Rosendaal FR . Venous thrombosis—the interaction of genes and environment. N Engl J Med. 1998; 338: 1840–1841.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM . A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–3703.
Franco RF, Reitsma PH . Genetic risk factors of venous thrombosis. Hum Genet. 2001; 109: 369–384.
Miranda-Vilela AL . Role of polymorphisms in factor V (FV Leiden), prothrombin, plasminogen activator inhibitor type-1 (PAI-1), methylenetetrahydrofolate reductase (MTHFR) and cystathionine â-synthase (CBS) genes as risk factors for thrombophilias. Mini Rev Med Chem 2012; 12: 997–1006.
Cattaneo M . Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006; 32: 716–723.
Eldibany MM, Caprini JA . Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007; 131: 872–884.
Lievers KJ, Boers GH, Verhoef P, den Heijer M, Kluijtmans LA, van der Put NM et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship toMTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med (Berl) 2001; 79: 522–528.
Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T . The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 468–477.
Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A . Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851–1855.
Decousus H, Moulin N, Quenet S, Bost V, Rivron-Guillot K, Laporte S et al. Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res 2007; 120: 51–61.
Al-Shamsi HO, Al Farsi A, Anjum M, Shen H, Zbuk K, Cook RJ et al. Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab. J Gastrointest Oncol 2015; 6: 274–279.
Suenaga M, Mizunuma N, Kobayashi K, Shinozaki E, Matsusaka S, Chin K et al. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Med Oncol 2010; 27: 807–814.
Khan S, Dickerman JD . Hereditary thrombophilia. Thromb J 2006; 4: 15.
Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ . Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 1996; 101: 406–412.
Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B . Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91–96.
Ravin AJ, Edwards RP, A Krohn M, Kelley JR, Christopherson WA, Roberts JM . The factor V leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol 2002; 100: 1285–1289.
Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 2004; 10: 1312–1317.
Ramacciotti E, Wolosker N, Puech-Leao P, Zeratti EA, Gusson PR, del Giglio A et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 2003; 109: 171–174.
Kennedy M, Andreescu AC, Greenblatt MS, Jiang H, Thomas CA, Chassereau L et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol 2005; 128: 386–388.
Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010; 21: 871–876.
Ozkan M, Sivgin S, Kocyigit I, Emirogullari F, Dikilitas M, Kaynar L et al. Do thrombophilic gene mutations have a role on thromboembolic events in cancer patients? Asia Pac J Clin Oncol 2012; 8: 34–41.
Eroglu A, Ulu A, Cam R, Kurtman C, Akar N . Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis 2007; 23: 31–34.
Eroglu A, Egin Y, Cam R, Akar N . The 19- bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis. Ann Hematol 2009; 88: 73–76.
Pihusch R, Danzl G, Scholz M, Harich D, Pihusch M, Lohse P et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002; 94: 3120–3126.
Lipay NV, Dmitriev VV, Borisenok MB . Thrombotic complications during cancer treatment in children. Exp Oncol 2007; 29: 231–235.
Blom JW, Doggen CJ, Osanto S, Rosendaal FR . Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722.
Eroglu A, Ulu A, Akar N . Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis. J Thromb Thrombolysis 2006; 22: 111–112.
Wang J, Wang C, Chen N, Shu C, Guo X, He Y et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venousthromboembolism: a meta-analysis. Thromb Res 2014; 134: 1241–1248.
Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ et al. Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. Thromb Res 2015; 136: 865–869.
Ferroni P, Palmirotta R, Riondino S, De Marchis ML, Nardecchia A, Formica V et al. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. Thromb Haemost 2015; 115: 143–151.
Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H . Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol 2011; 29: 1722–1727.
Khorana AA, Connolly GC . Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839–4847.
Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA . Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–1850.
Mandalà M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007; 18: 1660–1665.
Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL . Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990; 65: 425–432.
Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130–2135.
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website
About this article
Cite this article
Falvella, F., Cremolini, C., Miceli, R. et al. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics J 17, 331–336 (2017). https://doi.org/10.1038/tpj.2016.22